©The Author(s) 2020.
World J Clin Oncol. Oct 24, 2020; 11(10): 809-835
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.809
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.809
| Antibiotherapy | Indication |
| Antipseudomonal β-lactam agent (cefepime, ceftazidime) | All patients with febrile neutropenia |
| OR | |
| Carbapenem (meropenem or mipenem/cilastatin) | Hemodynamic instability |
| OR | |
| Piperacillin/tazobactam | |
| OR | |
| Novel cephalosporin/β-lactamase inhibitor (Ceftolozane/tazobactam or Ceftazidime/avibactam) | |
| PLUS | |
| Aminoglycosides (optional) | |
| PLUS | |
| Vancomycin | |
| Vancomycin, linezolid or daptomycin | Suspected catheter-related infections |
| Skin or soft-tissue infection | |
| Risk of methicillin-resistant Staphylococcus aureus | |
| Linezolid or daptomycin | Risk of vancomycin-resistant Enterococcus spp. |
| Carbapenem | Risk of extended-spectrum β-lactamase-producing gram negative bacteria |
| Polymyxin-colistin or tigecycline | Risk of Klebsiella pneumonia carbapenemase |
| Ciprofloxacin + clindamycin | Penicillin-allergic patients |
| OR | |
| Aztreonam + vancomycin | |
| Trimethoprim/sulfamethoxazole | Suspected Pneumocystis pneumonia |
| Antifungal drugs (echinocandins, amphotericin B lipid-based formulations) | Suspected invasive mycosis |
- Citation: Martos-Benítez FD, Soler-Morejón CD, Lara-Ponce KX, Orama-Requejo V, Burgos-Aragüez D, Larrondo-Muguercia H, Lespoir RW. Critically ill patients with cancer: A clinical perspective. World J Clin Oncol 2020; 11(10): 809-835
- URL: https://www.wjgnet.com/2218-4333/full/v11/i10/809.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i10.809